KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

Core Viewpoint - KalVista Pharmaceuticals has received marketing and manufacturing approval for EKTERLY® (sebetralstat) in Japan, marking a significant advancement in the treatment of hereditary angioedema (HAE) [1] Group 1: Product Approval - The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for EKTERLY® for the treatment of acute attacks of hereditary angioedema in adults and adolescents aged 12 years and older [1] - EKTERLY is noted as the first and only oral on-demand treatment for HAE approved in Japan [1]